Fresenius SE & Co KGaA (FRE) Given a €65.00 Price Target by Kepler Capital Markets Analysts

Fresenius SE & Co KGaA (FRA:FRE) received a €65.00 ($75.58) price objective from Kepler Capital Markets in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Kepler Capital Markets’ price target indicates a potential upside of 60.53% from the company’s current price.

Other analysts have also issued reports about the company. Sanford C. Bernstein set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, September 21st. Warburg Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, September 28th. Barclays set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, September 28th. Commerzbank set a €79.00 ($91.86) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, August 24th. Finally, Morgan Stanley set a €77.00 ($89.53) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday, September 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of €70.39 ($81.85).

Shares of FRE stock opened at €40.49 ($47.08) on Friday. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Growth Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply